Ikena Oncology, Inc. (IKNA)
Total Valuation
Ikena Oncology has a market cap or net worth of $67.08 million. The enterprise value is -$97.65 million.
Market Cap | 67.08M |
Enterprise Value | -97.65M |
Important Dates
The last earnings date was Tuesday, March 12, 2024, before market open.
Earnings Date | Mar 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 15.33% in one year.
Shares Outstanding | 48.26M |
Shares Change (YoY) | +15.33% |
Shares Change (QoQ) | +10.21% |
Owned by Insiders (%) | 7.00% |
Owned by Institutions (%) | 100.56% |
Float | 17.90M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.32 |
Forward PS | 8.05 |
PB Ratio | 0.40 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.58, with a Debt / Equity ratio of 0.06.
Current Ratio | 12.58 |
Quick Ratio | n/a |
Debt / Equity | 0.06 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.20% and return on invested capital (ROIC) is -41.78%.
Return on Equity (ROE) | -44.20% |
Return on Assets (ROA) | -37.30% |
Return on Capital (ROIC) | -41.78% |
Revenue Per Employee | $213,023 |
Profits Per Employee | -$1.59M |
Employee Count | 43 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | -162,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.39% in the last 52 weeks. The beta is 0.32, so Ikena Oncology's price volatility has been lower than the market average.
Beta (1Y) | 0.32 |
52-Week Price Change | -61.39% |
50-Day Moving Average | 1.44 |
200-Day Moving Average | 3.36 |
Relative Strength Index (RSI) | 43.17 |
Average Volume (30 Days) | 405,995 |
Short Selling Information
The latest short interest is 1.12 million, so 2.33% of the outstanding shares have been sold short.
Short Interest | 1.12M |
Short Previous Month | 974,014 |
Short % of Shares Out | 2.33% |
Short % of Float | 6.28% |
Short Ratio (days to cover) | 1.61 |
Income Statement
In the last 12 months, Ikena Oncology had revenue of $9.16 million and -$68.17 million in losses. Loss per share was -$1.63.
Revenue | 9.16M |
Gross Profit | 9.16M |
Operating Income | -75.42M |
Pretax Income | -68.33M |
Net Income | -68.17M |
EBITDA | -65.59M |
EBIT | -68.33M |
Loss Per Share | -$1.63 |
Balance Sheet
The company has $175.47 million in cash and $10.74 million in debt, giving a net cash position of $164.73 million or $3.41 per share.
Cash & Cash Equivalents | 175.47M |
Total Debt | 10.74M |
Net Cash | 164.73M |
Net Cash Per Share | $3.41 |
Equity / Book Value | 169.76M |
Book Value Per Share | 3.52 |
Working Capital | 164.46M |
Cash Flow
In the last 12 months, operating cash flow was -$79.74 million and capital expenditures -$414,000, giving a free cash flow of -$80.16 million.
Operating Cash Flow | -79.74M |
Capital Expenditures | -414,000 |
Free Cash Flow | -80.16M |
FCF Per Share | -$1.92 |
Margins
Gross margin is 100.00%, with operating and profit margins of -823.33% and -744.17%.
Gross Margin | 100.00% |
Operating Margin | -823.33% |
Pretax Margin | -745.94% |
Profit Margin | -744.17% |
EBITDA Margin | -716.09% |
EBIT Margin | -745.94% |
FCF Margin | -875.08% |
Dividends & Yields
Ikena Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -15.33% |
Shareholder Yield | -15.33% |
Earnings Yield | -101.62% |
FCF Yield | -119.50% |
Analyst Forecast
The average price target for Ikena Oncology is $10.67, which is 662.14% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $10.67 |
Price Target Difference | 662.14% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Revenue Growth Forecast (5Y) | 54.12% |
EPS Growth Forecast (5Y) | -13.70% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Ikena Oncology has an Altman Z-Score of -0.35 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.35 |
Piotroski F-Score | 1 |